Reduced transcription of CCL2, expression of CD163+ macrophages, and modulation of immune response factors, including IL-1, PBMC influx, TNF-α, GM-CSF levels, and CD73+ and CCR2+ monocytes, further support EV’s therapeutic potential for myocardial infarction. This evidence concerns the gene CCR2 and myocardial infarction.